Group 1 - Organon & Co. is initiated at Strong Buy with a price target of $26.4, highlighting its diversified portfolio in Rx therapies, particularly in women's health and biosimilars [1] - The investment thesis is supported by a forecasted operational inflection, indicating potential growth and performance improvement [1] - Moretus Research emphasizes a structured approach to equity research, focusing on companies with durable business models and mispriced cash flow potential [1] Group 2 - The research methodology combines rigorous fundamental analysis with a judgment-driven process, aiming to filter out noise and overly complex forecasting [1] - Valuation is based on sector-relevant multiples tailored to each company's business model, emphasizing comparability and simplicity [1] - Moretus Research targets underappreciated companies undergoing structural changes or temporary dislocations, which can lead to asymmetric returns [1]